Foreign Filer Report • May 6, 2024
Preview not available for this file type.
Download Source File6-K 1 f6k_050624.htm FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____
FORM 6-K
____
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 6, 2024
____
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
____
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Field: Page; Sequence: 1
Field: /Page
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details
of the person discharging managerial responsibilities/person closely associated | |
| --- | --- | --- |
| a) | Name of the Board member/Executive/Associated
Person | Novo Holdings A/S, associated to Kasim
Kutay |
| 2 | Reason for the notification | |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A&S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| Novo
Nordisk A/S Investor
Relations |
| --- |
| Company
announcement No 39 / 2024 |
Field: Page; Sequence: 2
Field: /Page
| a) | Description of
the financial instrument, type of instrument, Identification code | Shares Novo Nordisk B DK0062498333 | |
| --- | --- | --- | --- |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | | |
| | | Price(s) DKK 860.02 | Volume(s) 6,311,250 shares |
| d) | Aggregated information -
Aggregated volume -
Price | | |
| | | 6,311,250 shares DKK 5,427,801,225.00 | |
| e) | Date of the transaction | 2024-05-06 | |
| f) | Place of the transaction | Outside a trading venue | |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
|---|---|
| Ambre James-Brown +45 3079 9289 [email protected] | Liz Skrbkova (US) +1 609 917 0632 [email protected] |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 [email protected] | Jacob Martin Wiborg Rode +45 3075 5956 [email protected] |
| David Heiberg Landsted +45 3077 6915 [email protected] | Mark Joseph Root (US) +1 848 213 3219 [email protected] |
| Novo
Nordisk A/S Investor
Relations |
| --- |
| Company
announcement No 39 / 2024 |
Field: Page; Sequence: 3
Field: /Page
| Sina Meyer +45 3079 6656 [email protected] |
|---|
| Ida Melvold Gjøsund +45 3077 5649 [email protected] |
| Novo
Nordisk A/S Investor
Relations |
| --- |
| Company
announcement No 39 / 2024 |
Field: Page; Sequence: 4
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 6, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer
Field: Rule-Page
Field: /Rule-Page
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.